CLS:TSXCelestica Inc. Analysis
Data as of 2026-03-10 - not real-time
CA$371.15
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Celestica (CLS.TO) is trading around CAD 371, roughly 92% above its DCF‑derived fair value of CAD 194, indicating a substantial premium. The stock enjoys a robust revenue growth rate of 43.6% YoY and a forward PE of 21.2×, well below its current trailing PE of 38.2×, suggesting earnings momentum may help narrow the valuation gap. Technicals are mixed: the 20‑day SMA (382.5) sits above price, the 200‑day SMA (339.5) is below, RSI is neutral at 45, while the MACD histogram is negative, hinting at short‑term bearish pressure. Support sits near CAD 331 and resistance near CAD 440, framing a potential upside of about 52% if the price can break higher. Recent earnings beats and a raised 2026 revenue outlook to USD 17 bn are driven by AI‑focused data‑center demand, a narrative reinforced by multiple analyst upgrades and a “strong buy” consensus. However, the company is contending with a securities‑fraud investigation and a planned insider stock sale, which injects regulatory and governance risk into the mix. The balance sheet shows a high debt‑to‑equity of 41.4% and a beta exceeding 2.0, reflecting both leverage and heightened market sensitivity. Volatility is elevated at roughly 80% (30‑day), and cash flow remains solid with free cash flow near CAD 595 m. No dividend is paid, so income‑focused investors have no yield cushion. In summary, while growth catalysts are compelling, the stock’s premium valuation, legal headwinds, and market volatility temper enthusiasm.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD and price below 20‑day SMA
- Legal investigation and insider sale creating near‑term uncertainty
- Strong support at CAD 331 limiting downside
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Accelerating AI data‑center revenue growth
- Forward PE compression to ~21×
- Analyst consensus of strong‑buy with raised 2026 guidance
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Sustained high ROE (~40%) indicating competitive advantage
- Elevated beta and volatility suggesting price swings
- Regulatory risk from ongoing fraud investigation
Key Metrics & Analysis
Financial Health
Revenue Growth43.60%
Profit Margin6.72%
P/E Ratio38.2
ROE40.49%
ROA10.10%
Debt/Equity41.44
P/B Ratio14.1
Op. Cash FlowCA$659.5M
Free Cash FlowCA$595.3M
Industry P/E37.0
Technical Analysis
TrendNeutral
RSI45.7
SupportCA$330.79
ResistanceCA$440.00
MA 20CA$382.55
MA 50CA$404.41
MA 200CA$339.49
MACDBearish
VolumeStable
Fear & Greed Index77.86
Valuation
Fair ValueCA$193.90
Target PriceCA$565.35
Upside/Downside52.33%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.02
Volatility79.99%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.